Evidence map›Paper›PMID 30521975›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Yoshihiro Inamoto, Igor Petriček, Linda Burns, Saurabh Chhabra, Zachariah DeFilipp, Peiman Hematti, Alicia Rovó, Raquel Schears, Ami Shah, Vaibhav Agrawal and 40 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Massive periorbital edema following hematopoietic stem cell transplantation.American journal of ophthalmology case reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 10 countries.

Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. Electronic address: yinamoto@ncc.go.jp.
Igor PetričekDepartment of Ophthalmology, Zagreb University Clinical Hospital, Zagreb, Croatia.
Linda BurnsCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be the Match, Minneapolis, Minnesota.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Alicia RovóInselspital, Bern University Hospital, Bern, Switzerland.
Raquel SchearsDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota.
Ami ShahDivision of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, California.
Vaibhav AgrawalIndiana University Simon Cancer Center, Indianapolis, Indiana.
Aisha AhmedUniversity of California, San Francisco, California.
Ibrahim AhmedDepartment of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
Asim AliDepartment of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Hassan AlkhateebDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota.
Amer BeitinjanehUniversity of Miami, Miami, Florida.
Neel BhattCenter for International Blood and Marrow Transplant Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Dave BuchbinderDivision of Pediatrics Hematology, Children's Hospital of Orange County, Orange, California.
Michael ByrneDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Natalie CallanderUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
Kristina FahnehjelmDepartment of Clinical Neuroscience, Karolinska Institute, St Erik Eye Hospital, Stockholm, Sweden; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nosha FarhadfarUniversity of Florida Health Shands Hospital, Gainesville, Florida.
Robert Peter GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Shahrukh HashmiDepartment of Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, Kentucky.
Erich HornUniversity of Florida Health Shands Hospital, Gainesville, Florida.
Ann JakubowskiDivision of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Jason LawTufts Medical Center, Boston, Massachusetts.
Catherine LeeUtah Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Sunita NathanRush University Medical Center, Chicago, Illinois.
Olaf PenackDivison of Hematology and Oncology, Department of Internal Medicine, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
Ravi PingaliHouston Methodist Hospital, Houston, Texas.
Pinki PrasadLousiana State University Children's Hospital, New Orleans, Louisiana.
Drazen PulanicDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Seth RotzCincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Aditya ShreenivasDivision of Hematology and Oncology, Mount Sinai Hospital, New York, New York.
Amir SteinbergDivision of Hematology and Oncology, Mount Sinai Hospital, New York, New York.
Khalid TabbaraWilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland.
André TichelliHematology, University Hospital Basel, Basel, Switzerland.
Baldeep WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
Jean YaredBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Grzegorz W BasakDepartment of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Minoo BattiwallaHematology Branch, Sarah Cannon Center for Blood Cancer, Nashville, Tennessee.
Rafael DuarteHematopoietic Transplantation and Hemato-oncology Section, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bronwen E ShawCenter for International Blood and Marrow Transplant Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Nuria Valdés-SanzDepartment of Ophthalmology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
Medical College of Wisconsin · USHospital Universitario Puerta de Hierro Majadahonda · ESKing Faisal Specialist Hospital & Research Centre · SAMayo Clinic · USMount Sinai Hospital · USUF Health Shands Hospital · USUniversity Hospital Centre Zagreb · HRVanderbilt University Medical Center · USBaylor College of Medicine · USCharité - Universitätsmedizin Berlin · DEChildren's Hospital of New Orleans · USChildren's Hospital of Orange County · USChildren's Mercy Hospital · USCincinnati Children's Hospital Medical Center · USFred Hutch Cancer Center · USImperial College London · GBIndiana University Health · USJohns Hopkins University · USKarolinska Institutet · SELucile Packard Children's Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

Non-graft-versus-host disease (GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT) but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

Indexed as

Eye DiseasesHematopoietic Stem Cell TransplantationHumansIncidenceMass ScreeningPatient Care TeamRisk FactorsComplicationEyeHematopoietic cell transplantationPreventionReviewTreatment

Identifiers

PMID30521975
PMCPMC6511311
OpenAlexW2901087484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.